Given that angiogenesis is a key feature in gynecological neoplasms, and NTs act as direct and indirect angiogenic factors, it may be relevant to study whether TRK inhibitors can improve the efficacy of antiangiogenic drugs, especially in cervical cancers with a co-existing HIV infection. This evidence concerns the gene NTRK1 and HIV infectious disease.